Methods of international health technology assessment agencies for economic evaluations- a comparative analysis

被引:54
|
作者
Mathes, Tim [1 ]
Jacobs, Esther [1 ]
Morfeld, Jana-Carina [1 ]
Pieper, Dawid [1 ]
机构
[1] Univ Witten Herdecke, Fac Hlth, Sch Med, Inst Res Operat Med, D-51109 Cologne, Germany
来源
关键词
COST-EFFECTIVENESS; DECISION-MAKING; ASSESSMENT ORGANIZATIONS; KEY PRINCIPLES; GUIDELINES; CARE; GENERALIZABILITY; UNCERTAINTY;
D O I
10.1186/1472-6963-13-371
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The number of Health Technology Assessment (HTA) agencies increases. One component of HTAs are economic aspects. To incorporate economic aspects commonly economic evaluations are performed. A convergence of recommendations for methods of health economic evaluations between international HTA agencies would facilitate the adaption of results to different settings and avoid unnecessary expense. A first step in this direction is a detailed analysis of existing similarities and differences in recommendations to identify potential for harmonization. The objective is to provide an overview and comparison of the methodological recommendations of international HTA agencies for economic evaluations. Methods: The webpages of 127 international HTA agencies were searched for guidelines containing recommendations on methods for the preparation of economic evaluations. Additionally, the HTA agencies were requested information on methods for economic evaluations. Recommendations of the included guidelines were extracted in standardized tables according to 13 methodological aspects. All process steps were performed independently by two reviewers. Results: Finally 25 publications of 14 HTA agencies were included in the analysis. Methods for economic evaluations vary widely. The greatest accordance could be found for the type of analysis and comparator. Cost-utility-analyses or cost-effectiveness-analyses are recommended. The comparator should continuously be usual care. Again the greatest differences were shown in the recommendations on the measurement/sources of effects, discounting and in the analysis of sensitivity. The main difference regarding effects is the focus either on efficacy or effectiveness. Recommended discounting rates range from 1.5% - 5% for effects and 3% - 5% for costs whereby it is mostly recommended to use the same rate for costs and effects. With respect to the analysis of sensitivity the main difference is that oftentimes the probabilistic or deterministic approach is recommended exclusively. Methods for modeling are only described vaguely and mainly with the rational that the "appropriate model" depends on the decision problem. Considering all other aspects a comparison is challenging as recommendations vary regarding detailedness and addressed issues. Conclusion: There is a considerable unexplainable variance in recommendations. Further effort is needed to harmonize methods for preparing economic evaluations.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] What aspects of the health technology assessment process recommended by international health technology assessment agencies received the most attention in Poland in 2008?
    Kolasa, Katarzyna
    Dziomdziora, Malgorzata
    Fajutrao, Liberty
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2011, 27 (01) : 84 - 94
  • [22] Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies
    Ciani, Oriana
    Grigore, Bogdan
    Blommestein, Hedwig
    de Groot, Saskia
    Mollenkamp, Meilin
    Rabbe, Stefan
    Daubner-Bendes, Rita
    Taylor, Rod S.
    MEDICAL DECISION MAKING, 2021, 41 (04) : 439 - 452
  • [23] History of the international societies in health technology assessment: International Society for Technology Assessment in Health Care and Health Technology Assessment International
    Banta, David
    Jonsson, Egon
    Childs, Paul
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2009, 25 : 19 - 23
  • [24] COST-EFFECTIVENESS EVALUATIONS OF CAR-T CELL THERAPIES BY HEALTH TECHNOLOGY ASSESSMENT AGENCIES
    Dorneles, G.
    de Araujo, C. L. P.
    Schneider, N. B.
    Falavigna, M.
    VALUE IN HEALTH, 2024, 27 (06) : S88 - S88
  • [25] Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies
    Egilman, Alexander C.
    Wallach, Joshua D.
    Dhruva, Sanket S.
    Gonsalves, Gregg S.
    Ross, Joseph S.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2019, 34 (11) : 2319 - 2321
  • [26] EVALUATION OF PATIENT AND PUBLIC INVOLVEMENT INITIATIVES IN HEALTH TECHNOLOGY ASSESSMENT: A SURVEY OF INTERNATIONAL AGENCIES
    Weeks, Laura
    Polisena, Julie
    Scott, Anna Mae
    Holtorf, Anke-Peggy
    Staniszewska, Sophie
    Facey, Karen
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2017, 33 (06) : 715 - 723
  • [27] Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies
    Alexander C. Egilman
    Joshua D. Wallach
    Sanket S. Dhruva
    Gregg S. Gonsalves
    Joseph S. Ross
    Journal of General Internal Medicine, 2019, 34 : 2319 - 2321
  • [28] METHODS FOR HEALTH ECONOMIC EVALUATIONS OF VACCINES - RESULTS FROM AN INTERNATIONAL EXPERT-WORKSHOP
    Ultsch, B.
    Damm, O.
    Beutels, P.
    Bilcke, P.
    Brueggenjuergen, B.
    Gerber-Grote, A. U.
    Greiner, W.
    Hanquet, G.
    Harder, T.
    Hutubessy, R.
    Jit, M.
    Knol, M.
    Kuhlmann, A.
    von Kries, R.
    Levy-Bruhl, D.
    Perleth, M.
    Postma, M. J.
    Salo, H.
    Siebert, U.
    Wasem, J.
    Weidemann, F.
    Wichmann, O.
    VALUE IN HEALTH, 2014, 17 (07) : A552 - A552
  • [29] Economic Evaluations in the EURONHEED A Comparative Analysis
    Hutter, Florencia
    Antonanzas, Fernando
    PHARMACOECONOMICS, 2009, 27 (07) : 561 - 570
  • [30] Economic Evaluations in the EURONHEEDA Comparative Analysis
    Florencia Hutter
    Fernando Antoñanzas
    PharmacoEconomics, 2009, 27 : 561 - 570